Tiziana Life Sciences Ltd Com Stock Price, News & Analysis

Tiziana Life Sciences (NASDAQ: TLSA) announced its participation in Biotech Showcase 2021, providing on-demand presentations for attendees. Dr. Kunwar Shailubhai, CEO, stated that topline data from a COVID-19 trial is expected this month, with several Phase 2 trial launches planned for 2021. With the potential application of Foralumab in various autoimmune diseases, the company aims to achieve significant milestones impacting its valuation. Biotech Showcase serves as a networking platform for life science professionals and investors, promoting innovations in drug discovery.

Tiziana Life Sciences (Nasdaq: TLSA) has completed a clinical study in Brazil on nasally administered Foralumab for COVID-19 patients. The trial showed positive anecdotal feedback from patients, highlighting rapid improvement in smell sensation, a common COVID-19 symptom. The study involved 39 patients with moderate to severe COVID-19, assessing safety and efficacy against the disease. Topline data is expected in January 2021, with implications for treating coronaviruses as well as potential applications in other diseases. This novel approach aims to enhance the immune response against COVID-19 variants.

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) announces its admission of ordinary shares to the Official List of the FCA and the Main Market of the London Stock Exchange. The prospectus for this listing was approved on December 18, 2020. Key dates include the last day of trading on AIM on January 20, 2021, with delisting and trading on the Main Market commencing on January 21, 2021, at 8:00 am. Tiziana is focused on innovative therapeutics for oncology and other diseases, including advancing clinical studies for its unique fully human anti-CD3 monoclonal antibody for various conditions.

Tiziana Life Sciences (Nasdaq: TLSA) has announced its application for a standard listing on the Official List of the FCA and trading admission on the London Stock Exchange's Main Market. The company will cancel AIM trading, effective January 21, 2021, and will not issue new shares during this transition. The prospectus is expected to be published on December 18, 2020. Tiziana focuses on innovative therapeutics for oncology, inflammation, and infectious diseases, with phase 2 studies planned for its drug, foralumab.

Tiziana Life Sciences plc (NASDAQ: TLSA), a biotechnology company specializing in therapeutics for oncology and infectious diseases, announced a conference call led by CEO and CSO Dr. Kunwar Shailubhai on December 2, 2020, at 4:15 p.m. ET. The call will cover the company's transition from AIM to the London Stock Exchange's Standard Segment, updates on ongoing clinical trials, and recent developments. Individuals unable to attend can access a replay until December 16, 2020. The company is known for its innovative treatments, including Milciclib and Foralumab, addressing various autoimmune diseases.

Tiziana Life Sciences has disclosed that Gabriele Cerrone, Executive Chairman, acquired 45,000 ordinary shares at 84p each on November 18, 2020. This purchase increased Cerrone's shareholding from 34.029% to 34.052%, just above the 1% threshold under the UK Takeover Code. The acquisition reflects Cerrone's continued confidence in the company's prospects within the biotechnology sector, which focuses on oncology and infectious diseases.

Tiziana Life Sciences (Nasdaq: TLSA) announced a collaboration with Parexel to conduct a global Phase 1b/2 trial using take-home capsules of Foralumab, the only fully human anti-CD3 monoclonal antibody, for moderate to severe Crohn's Disease.

This study will enroll 60 patients across the U.S. and Europe, aiming to evaluate safety and efficacy. The Crohn's Disease therapeutics market is projected to reach $4.7 billion by 2025, emphasizing the potential of Foralumab as a safer alternative to intravenous therapies, improving patient compliance and outcomes.

Tiziana Life Sciences (Nasdaq: TLSA) announced a clinical study for nasally administered Foralumab in COVID-19 patients in Brazil, starting November 3, 2020. This collaboration includes Harvard Medical School and aims to address Brazil's critical COVID-19 situation, with nearly 5.5 million cases reported. The trial seeks to demonstrate the drug's potential to enhance nasal immunity and suppress inflammation associated with the disease. Clinical data is anticipated by year-end, following a patent filed for its use in COVID-19 treatment.

Tiziana Life Sciences plc (Nasdaq: TLSA) has announced the timetable for the demerger of Accustem Sciences Limited, which involves spinning off its StemPrintER technology for predicting breast cancer recurrence. The StemPrintER demonstrated superior accuracy over Oncotype DX in predicting the 10-year risk for over 800 ER+/HER2-breast cancer patients. Key dates for the demerger include October 27, 2020, for court approval, and November 6, 2020, as the record date for ADR holders. A new ADR program for Accustem is in the works, with expected timelines aligned for effective registration and trading.